Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.43 |
| ▸ | SQLE | Q14534 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14768438 | 0.83 | KMT2A (0.48) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL14767595 | 0.76 | KMT2A (0.47) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL14768441 | 0.75 | KMT2A (0.46) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL14768450 | 0.75 | KMT2A (0.46) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL14767533 | 0.71 | KMT2A (0.53) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL14768418 | 0.71 | KMT2A (0.53) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL10869285 | 0.71 | KMT2A (0.53) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL14767563 | 0.71 | KMT2A (0.53) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL10869279 | 0.71 | KMT2A (0.53) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11856631 | 0.70 | KMT2A (0.52) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371301-B2 | Prenylarene compound and use thereof | OSAKA UNIVERSITY (JP) | 2016-06-21 | — | — | US | disclosed |
| US-9371301-B2 | Prenylarene compound and use thereof | OSAKA UNIVERSITY (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20130065937-A1 | NOVEL PRENYLARENE COMPOUND AND USE THEREOF | OSAKA UNIVERSITY (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20130065937-A1 | NOVEL PRENYLARENE COMPOUND AND USE THEREOF | OSAKA UNIVERSITY (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065937-A1 | NOVEL PRENYLARENE COMPOUND AND USE THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NR1H3, HIF1AN | KMT2A 1404/4885MAPT 4854/4885MEN1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.